DekaBank Deutsche Girozentrale boosted its position in Hologic, Inc. (NASDAQ:HOLX) by 41.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 505,635 shares of the medical equipment provider’s stock after buying an additional 148,105 shares during the period. DekaBank Deutsche Girozentrale owned about 0.18% of Hologic worth $23,054,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. TrimTabs Asset Management LLC increased its stake in Hologic by 88.8% in the first quarter. TrimTabs Asset Management LLC now owns 2,993 shares of the medical equipment provider’s stock worth $127,000 after buying an additional 1,408 shares during the last quarter. Beck Mack & Oliver LLC purchased a new stake in Hologic during the second quarter worth $209,000. Notis McConarty Edward purchased a new stake in Hologic during the second quarter worth $213,000. Advisor Partners LLC purchased a new stake in Hologic during the first quarter worth $201,000. Finally, CAPROCK Group Inc. purchased a new stake in Hologic during the second quarter worth $214,000. Institutional investors own 94.46% of the company’s stock.
Shares of Hologic, Inc. (NASDAQ:HOLX) opened at 38.20 on Friday. The company has a market cap of $10.71 billion, a P/E ratio of 14.23 and a beta of 0.90. Hologic, Inc. has a 12-month low of $35.15 and a 12-month high of $46.80. The company has a 50-day moving average price of $43.73 and a 200-day moving average price of $42.89.
Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The business had revenue of $806.10 million during the quarter, compared to analyst estimates of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. Hologic’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period last year, the company earned $0.51 EPS. On average, analysts predict that Hologic, Inc. will post $2.01 earnings per share for the current year.
A number of equities research analysts have recently weighed in on the company. Royal Bank Of Canada restated a “sector perform” rating and set a $45.00 target price (down previously from $50.00) on shares of Hologic in a research report on Wednesday. BidaskClub downgraded Hologic from a “hold” rating to a “sell” rating in a research report on Wednesday. Deutsche Bank AG dropped their target price on Hologic from $51.00 to $49.00 and set a “buy” rating for the company in a research report on Thursday, August 3rd. Barclays PLC restated an “equal weight” rating and set a $51.00 target price (down previously from $53.00) on shares of Hologic in a research report on Wednesday. Finally, Jefferies Group LLC set a $49.00 target price on Hologic and gave the stock a “buy” rating in a research report on Sunday, May 28th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $48.64.
In related news, Director Elaine Ullian sold 6,902 shares of the firm’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total transaction of $276,908.24. Following the completion of the transaction, the director now directly owns 23,810 shares of the company’s stock, valued at approximately $955,257.20. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Lawrence M. Levy sold 9,076 shares of the firm’s stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $42.80, for a total value of $388,452.80. Following the transaction, the director now directly owns 43,165 shares of the company’s stock, valued at $1,847,462. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 60,627 shares of company stock valued at $2,632,911. 0.79% of the stock is owned by corporate insiders.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.